Recruiting

Testing a new cancer-fighting medication alone and with immunotherapy

Plain-English translation of NCT07749586 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This research study is testing a new experimental medication called to see if it can help your immune system recognize and destroy cancer cells. You'll either take the medication by itself as a tablet, or take it combined with another well-known cancer immunotherapy drug called . Researchers believe this medication works by helping your body's natural defenses fight advanced solid tumors more effectively.

Many patients with advanced cancers have exhausted standard treatment options or don't respond well to existing therapies. This medication is designed to unlock a different pathway in your immune system that hasn't been targeted before, offering hope for patients who need new treatment approaches.

Do you qualify?

You likely qualify if…

you have been diagnosed with an advanced solid tumor that cannot be surgically removed or has spread
you have previously received at least one immunotherapy drug targeting your immune system's checkpoint pathways
you have received standard cancer treatments appropriate for your disease type, or your doctor believes you won't benefit from or tolerate standard options
your cancer has shown growth on recent imaging scans, and you have at least one measurable tumor spot that hasn't been previously treated with radiation
you are in generally good overall health with minimal limitations in your ability to perform daily activities

You likely don't qualify if…

you have active brain tumors or cancer spread to the brain that is getting worse or needs immediate treatment
you have an active autoimmune disease or a history of severe immune-related side effects from previous immunotherapy drugs
you are allergic or have had severe reactions to pembrolizumab or similar immunotherapy medications
you have received cancer treatment or radiation within the past 2 weeks
you have certain heart rhythm problems on your electrocardiogram that could make the study unsafe

What participation looks like

You will take the medication as a tablet by mouth once daily on an empty stomach, in 21-day treatment cycles. Depending on which group you're assigned to, you may receive only the tablet, or the tablet plus given through an IV infusion or under-the-skin injection every three weeks. You'll continue treatment until your cancer progresses, you experience unacceptable side effects, or you decide to withdraw. The study includes multiple phases: early phases will test different dose levels to find the safest and most effective dose, and later phases will focus on specific cancer types.

Testing a new cancer-fighting medication alone and with immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(3 sites)